DNA damage and pulmonary hypertension

International Journal of Molecular Sciences

Volumn 17, Issue 6, 2016, Pages

  Ranchoux, Benoît ^a   Meloche, Jolyane ^a   Paulin, Roxane ^a   Boucherat, Olivier ^a   Provencher, Steeve ^a   Bonnet, Sébastien ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

DNA damage; DNA damage response; Inflammation; Oxidative stress; Pulmonary hypertension

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALKYLATING AGENT; ANOREXIGENIC AGENT; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; ENDOTHELIN 1; EXTRACELLULAR SUPEROXIDE DISMUTASE; FIBROBLAST GROWTH FACTOR 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MITOCHONDRIAL DNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NUTLIN 3; PIFITHRIN ALPHA; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SEROTONIN UPTAKE INHIBITOR; SIRTUIN 3; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VELIPARIB;

APOPTOSIS; CELL PROLIFERATION; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DOWN REGULATION; HUMAN; INFLAMMATION; MITOCHONDRIAL RESPIRATION; MITOPHAGY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; PULMONARY VENO-OCCLUSIVE DISEASE; REVIEW; SINGLE STRANDED DNA BREAK; UPREGULATION; ANIMAL; GENETICS; METABOLISM; MITOCHONDRIAL GENE; PATHOLOGY;

ANIMALS; DNA DAMAGE; DNA REPAIR; GENES, MITOCHONDRIAL; HUMANS; HYPERTENSION, PULMONARY; OXIDATIVE STRESS;

EID: 84975815562     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17060990     Document Type: Review

References (308)

1. Hoeper, M.M., Humbert, M., Souza, R., Idrees, M., Kawut, S.M., Sliwa-Hahnle, K., Jing, Z.-C., Gibbs, J.S.R. A global view of pulmonary hypertension. Lancet Respir. Med. 2016. [CrossRef]
2. Hoeper, M.M., McLaughlin, V.V., Dalaan, A.M.A., Satoh, T., Galiè, N. Treatment of pulmonary hypertension. Lancet Respir. Med. 2016. [CrossRef]
3. Tuder, R.M., Archer, S.L., Dorfmüller, P., Erzurum, S.C., Guignabert, C., Michelakis, E., Rabinovitch, M., Schermuly, R., Stenmark, K.R., Morrell, N.W. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J. Am. Coll. Cardiol. 2013, 62, D4–D12. [CrossRef] [PubMed]
4. Humbert, M., Montani, D., Perros, F., Dorfmüller, P., Adnot, S., Eddahibi, S. Endothelial cell dysfunction and cross talk between endothelium and smooth muscle cells in pulmonary arterial hypertension. Vascul. Pharmacol. 2008, 49, 113–118. [CrossRef] [PubMed]
5. Rabinovitch, M. Molecular pathogenesis of pulmonary arterial hypertension. J. Clin. Investig. 2012, 122, 4306–4313. [CrossRef] [PubMed]
6. Cohen-Kaminsky, S., Hautefort, A., Price, L., Humbert, M., Perros, F. Inflammation in pulmonary hypertension: What we know and what we could logically and safely target first. Drug Discov. Today 2014, 19, 1251–1256. [CrossRef] [PubMed]
7. Ryan, J., Dasgupta, A., Huston, J., Chen, K.-H., Archer, S.L. Mitochondrial dynamics in pulmonary arterial hypertension. J. Mol. Med. 2015, 93, 229–242. [CrossRef] [PubMed]
8. Potus, F., Ruffenach, G., Dahou, A., Thebault, C., Breuils-Bonnet, S., Tremblay, È., Nadeau, V., Paradis, R., Graydon, C., Wong, R., et al. Downregulation of MicroRNA-126 Contributes to the Failing Right Ventricle in Pulmonary Arterial Hypertension. Circulation 2015, 132, 932–943. [CrossRef] [PubMed]
9. Potus, F., Malenfant, S., Graydon, C., Mainguy, V., Tremblay, È., Breuils-Bonnet, S., Ribeiro, F., Porlier, A., Maltais, F., Bonnet, S., et al. Impaired angiogenesis and peripheral muscle microcirculation loss contribute to exercise intolerance in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2014, 190, 318–328. [CrossRef] [PubMed]
10. Ranchoux, B., Antigny, F., Rucker-Martin, C., Hautefort, A., Péchoux, C., Bogaard, H.J., Dorfmüller, P., Remy, S., Lecerf, F., Planté, S., et al. Endothelial-to-mesenchymal transition in pulmonary hypertension. Circulation 2015, 131, 1006–1018. [CrossRef] [PubMed]
11. Kherbeck, N., Tamby, M.C., Bussone, G., Dib, H., Perros, F., Humbert, M., Mouthon, L. The role of inflammation and autoimmunity in the pathophysiology of pulmonary arterial hypertension. Clin. Rev. Allergy Immunol. 2013, 44, 31–38. [CrossRef] [PubMed]
12. Malenfant, S., Neyron, A.-S., Paulin, R., Potus, F., Meloche, J., Provencher, S., Bonnet, S. Signal transduction in the development of pulmonary arterial hypertension. Pulm. Circ. 2013, 3, 278–293. [CrossRef] [PubMed]
13. Perros, F., Humbert, M., Cohen-Kaminsky, S. Pulmonary arterial hypertension: A flavor of autoimmunity. Méd. Sci. 2013, 29, 607–616.
14. Montani, D., Günther, S., Dorfmüller, P., Perros, F., Girerd, B., Garcia, G., Jaïs, X., Savale, L., Artaud-Macari, E., Price, L.C., et al. Pulmonary arterial hypertension. Orphanet J. Rare Dis. 2013, 8, 97. [CrossRef] [PubMed]
15. Montani, D., Chaumais, M.-C., Guignabert, C., Günther, S., Girerd, B., Jaïs, X., Algalarrondo, V., Price, L.C., Savale, L., Sitbon, O., et al. Targeted therapies in pulmonary arterial hypertension. Pharmacol. Ther. 2014, 141, 172–191. [CrossRef] [PubMed]
16. Humbert, M., Sitbon, O., Chaouat, A., Bertocchi, M., Habib, G., Gressin, V., Yaïci, A., Weitzenblum, E., Cordier, J.-F., Chabot, F., et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010, 122, 156–163. [CrossRef] [PubMed]
17. Rabinovitch, M., Guignabert, C., Humbert, M., Nicolls, M.R. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ. Res. 2014, 115, 165–175. [CrossRef] [PubMed]
18. Intengan, H.D., Schiffrin, E.L. Vascular remodeling in hypertension: Roles of apoptosis, inflammation, and fibrosis. Hypertension 2001, 38, 581–587. [CrossRef] [PubMed]
19. Lodish, H., Berk, A., Zipursky, S.L., Matsudaira, P., Baltimore, D., Darnell, J. DNA Damage and Repair and Their Role in Carcinogenesis. In Molecular Cell Biology, W.H. Freeman: New York, NY, USA, 2000.
20. Vaillancourt, M., Ruffenach, G., Meloche, J., Bonnet, S.: Adaptation and remodelling of the pulmonary circulation in pulmonary hypertension. Can. J. Cardiol. 2015, 31, 407–415. [CrossRef] [PubMed]
21. Lindahl, T. Instability and decay of the primary structure of DNA. Nature 1993, 362, 709–715. [CrossRef] [PubMed]
22. Esterbauer, H., Eckl, P., Ortner, A. Possible mutagens derived from lipids and lipid precursors. Mutat. Res. 1990, 238, 223–233. [CrossRef]
23. Holliday, R., Ho, T.: Gene silencing and endogenous DNA methylation in mammalian cells. Mutat. Res. 1998, 400, 361–368. [CrossRef]
24. De Bont, R., van Larebeke, N.: Endogenous DNA damage in humans: A review of quantitative data. Mutagenesis 2004, 19, 169–185. [CrossRef] [PubMed]
25. Hoeijmakers, J.H.J.: DNA damage, aging, and cancer. N. Engl. J. Med. 2009, 361, 1475–1485. [CrossRef] [PubMed]
26. Ribezzo, F., Shiloh, Y., Schumacher, B. Systemic DNA damage responses in aging and diseases. Semin. Cancer Biol. 2016. [CrossRef] [PubMed]
27. Helleday, T., Eshtad, S., Nik-Zainal, S. Mechanisms underlying mutational signatures in human cancers. Nat. Rev. Genet. 2014, 15, 585–598. [CrossRef] [PubMed]
28. Lindahl, T., Nyberg, B. Rate of depurination of native deoxyribonucleic acid. Biochemistry 1972, 11, 3610–3618. [CrossRef] [PubMed]
29. Boiteux, S., Guillet, M. Abasic sites in DNA: Repair and biological consequences in Saccharomyces cerevisiae. DNA Repair 2004, 3, 1–12. [CrossRef] [PubMed]
30. Caldecott, K.W.: Single-strand break repair and genetic disease. Nat. Rev. Genet. 2008, 9, 619–631.[PubMed]
31. Negritto, C. Double-Strand Breaks in DNA Can Be Lethal to a Cell. How Do Cells Fix Them? Available online: http://www.nature.com/scitable/topicpage/repairing-double-strand-dna-breaks-14432332 (accessed on 23 March 2016).
32. Stingele, J., Jentsch, S. DNA-protein crosslink repair. Nat. Rev. Mol. Cell Biol. 2015, 16, 455–460. [CrossRef]
33. Noll, D.M., Mason, T.M., Miller, P.S.: Formation and repair of interstrand cross-links in DNA. Chem. Rev. 2006, 106, 277–301. [CrossRef] [PubMed]
34. Lenart, P., Krejci, L. DNA, the central molecule of aging. Mutat. Res. 2016, 786, 1–7. [CrossRef] [PubMed]
35. Rouse, J., Jackson, S.P. Interfaces between the detection, signaling, and repair of DNA damage. Science 2002, 297, 547–551. [CrossRef] [PubMed]
36. Harrison, J.C., Haber, J.E. Surviving the breakup: The DNA damage checkpoint. Annu. Rev. Genet. 2006, 40, 209–235. [CrossRef] [PubMed]
37. Harper, J.W., Elledge, S.J. The DNA damage response: Ten years after. Mol. Cell 2007, 28, 739–745. [CrossRef] [PubMed]
38. McKinnon, P.J., Caldecott, K.W.: DNA strand break repair and human genetic disease. Annu. Rev. Genom. Hum. Genet. 2007, 8, 37–55. [CrossRef] [PubMed]
39. Wilson, D.M., Barsky, D. The major human abasic endonuclease: Formation, consequences and repair of abasic lesions in DNA. Mutat. Res. 2001, 485, 283–307. [CrossRef]
40. Demple, B., Sung, J.-S. Molecular and biological roles of Ape1 protein in mammalian base excision repair. DNA Repair 2005, 4, 1442–1449. [CrossRef] [PubMed]
41. Izumi, T., Wiederhold, L.R., Roy, G., Roy, R., Jaiswal, A., Bhakat, K.K., Mitra, S., Hazra, T.K. Mammalian DNA base excision repair proteins: Their interactions and role in repair of oxidative DNA damage. Toxicology 2003, 193, 43–65. [CrossRef]
42. Dianov, G.L., Sleeth, K.M., Dianova, I.I., Allinson, S.L. Repair of abasic sites in DNA. Mutat. Res. 2003, 531, 157–163. [CrossRef] [PubMed]
43. Kim, Y.-J., Wilson, D.M. Overview of base excision repair biochemistry. Curr. Mol. Pharmacol. 2012, 5, 3–13. [CrossRef] [PubMed]
44. Ménissier-de Murcia, J., Molinete, M., Gradwohl, G., Simonin, F., de Murcia, G. Zinc-binding domain of poly(ADP-ribose)polymerase participates in the recognition of single strand breaks on DNA. J. Mol. Biol. 1989, 210, 229–233. [CrossRef]
45. Khodyreva, S.N., Prasad, R., Ilina, E.S., Sukhanova, M.V., Kutuzov, M.M., Liu, Y., Hou, E.W., Wilson, S.H., Lavrik, O.I. Apurinic/apyrimidinic (AP) site recognition by the 51-dRP/AP lyase in poly(ADP-ribose) polymerase-1 (PARP-1). Proc. Natl. Acad. Sci. USA 2010, 107, 22090–22095. [CrossRef] [PubMed]
46. Fisher, A.E.O., Hochegger, H., Takeda, S., Caldecott, K.W. Poly(ADP-ribose) polymerase 1 accelerates single-strand break repair in concert with poly(ADP-ribose) glycohydrolase. Mol. Cell. Biol. 2007, 27, 5597–5605. [CrossRef] [PubMed]
47. Dianova, I.I., Sleeth, K.M., Allinson, S.L., Parsons, J.L., Breslin, C., Caldecott, K.W., Dianov, G.L. XRCC1-DNA polymerase beta interaction is required for efficient base excision repair. Nucleic Acids Res. 2004, 32, 2550–2555. [CrossRef] [PubMed]
48. Caldecott, K.W., Aoufouchi, S., Johnson, P., Shall, S. XRCC1 polypeptide interacts with DNA polymerase beta and possibly poly (ADP-ribose) polymerase, and DNA ligase III is a novel molecular “nick-sensor” in vitro. Nucleic Acids Res. 1996, 24, 4387–4394. [CrossRef] [PubMed]
49. Masson, M., Niedergang, C., Schreiber, V., Muller, S., Menissier-de Murcia, J., de Murcia, G. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol. Cell. Biol. 1998, 18, 3563–3571. [CrossRef] [PubMed]
50. Beneke, S. Regulation of chromatin structure by poly(ADP-ribosyl)ation. Front. Genet. 2012, 3, 169. [CrossRef] [PubMed]
51. Rouleau, M., Patel, A., Hendzel, M.J., Kaufmann, S.H., Poirier, G.G. PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer 2010, 10, 293–301. [CrossRef] [PubMed]
52. Schreiber, V., Dantzer, F., Ame, J.-C., de Murcia, G. Poly(ADP-ribose): Novel functions for an old molecule. Nat. Rev. Mol. Cell Biol. 2006, 7, 517–528. [CrossRef] [PubMed]
53. Marteijn, J.A., Lans, H., Vermeulen, W., Hoeijmakers, J.H.J. Understanding nucleotide excision repair and its roles in cancer and ageing. Nat. Rev. Mol. Cell Biol. 2014, 15, 465–481. [CrossRef] [PubMed]
54. Torgovnick, A., Schumacher, B. DNA repair mechanisms in cancer development and therapy. Front. Genet. 2015, 6, 157. [CrossRef] [PubMed]
55. Hanawalt, P.C., Spivak, G. Transcription-coupled DNA repair: Two decades of progress and surprises. Nat. Rev. Mol. Cell Biol. 2008, 9, 958–970. [CrossRef] [PubMed]
56. Knoch, J., Kamenisch, Y., Kubisch, C., Berneburg, M. Rare hereditary diseases with defects in DNA-repair. Eur. J. Dermatol. 2012, 22, 443–455.[PubMed]
57. Guillotin, D., Martin, S.A. Exploiting DNA mismatch repair deficiency as a therapeutic strategy. Exp. Cell Res. 2014, 329, 110–115. [CrossRef] [PubMed]
58. Li, G.-M. Mechanisms and functions of DNA mismatch repair. Cell Res. 2008, 18, 85–98. [CrossRef] [PubMed]
59. Modrich, P., Lahue, R. Mismatch repair in replication fidelity, genetic recombination, and cancer biology. Annu. Rev. Biochem. 1996, 65, 101–133. [CrossRef] [PubMed]
60. Kunkel, T.A., Erie, D.A.: DNA mismatch repair. Annu. Rev. Biochem. 2005, 74, 681–710. [CrossRef] [PubMed]
61. Jiricny, J. The multifaceted mismatch-repair system. Nat. Rev. Mol. Cell Biol. 2006, 7, 335–346. [CrossRef] [PubMed]
62. Iyama, T., Wilson, D.M. DNA repair mechanisms in dividing and non-dividing cells. DNA Repair 2013, 12, 620–636. [CrossRef] [PubMed]
63. Arnheim, N., Shibata, D. DNA mismatch repair in mammals: Role in disease and meiosis. Curr. Opin. Genet. Dev. 1997, 7, 364–370. [CrossRef]
64. Peltomäki, P. DNA mismatch repair and cancer. Mutat. Res. 2001, 488, 77–85. [CrossRef]
65. Ding, Q., Reddy, Y.V.R., Wang, W., Woods, T., Douglas, P., Ramsden, D.A., Lees-Miller, S.P., Meek, K. Autophosphorylation of the catalytic subunit of the DNA-dependent protein kinase is required for efficient end processing during DNA double-strand break repair. Mol. Cell. Biol. 2003, 23, 5836–5848. [CrossRef] [PubMed]
66. Helleday, T., Lo, J., van Gent, D.C., Engelward, B.P. DNA double-strand break repair: From mechanistic understanding to cancer treatment. DNA Repair 2007, 6, 923–935. [CrossRef] [PubMed]
67. Deriano, L., Roth, D.B. Modernizing the nonhomologous end-joining repertoire: Alternative and classical NHEJ share the stage. Annu. Rev. Genet. 2013, 47, 433–455. [CrossRef] [PubMed]
68. Nicolai, S., Rossi, A., di Daniele, N., Melino, G., Annicchiarico-Petruzzelli, M., Raschellà, G. DNA repair and aging: The impact of the p53 family. Aging 2015, 7, 1050–1065. [CrossRef] [PubMed]
69. Ahnesorg, P., Smith, P., Jackson, S.P. XLF interacts with the XRCC4-DNA ligase IV complex to promote DNA nonhomologous end-joining. Cell 2006, 124, 301–313. [CrossRef] [PubMed]
70. Roy, S., de Melo, A.J., Xu, Y., Tadi, S.K., Négrel, A., Hendrickson, E., Modesti, M., Meek, K. XRCC4/XLF Interaction is variably required for DNA repair and is not required for ligase IV stimulation. Mol. Cell. Biol. 2015, 35, 3017–3028. [CrossRef] [PubMed]
71. Della-Maria, J., Zhou, Y., Tsai, M.-S., Kuhnlein, J., Carney, J.P., Paull, T.T., Tomkinson, A.E. Human Mre11/human Rad50/Nbs1 and DNA ligase IIIalpha/XRCC1 protein complexes act together in an alternative nonhomologous end joining pathway. J. Biol. Chem. 2011, 286, 33845–33853. [CrossRef] [PubMed]
72. Boboila, C., Alt, F.W., Schwer, B. Classical and alternative end-joining pathways for repair of lymphocyte-specific and general DNA double-strand breaks. Adv. Immunol. 2012, 116, 1–49.[PubMed]
73. Metzger, M.J., Stoddard, B.L., Monnat, R.J. PARP-mediated repair, homologous recombination, and back-up non-homologous end joining-like repair of single-strand nicks. DNA Repair 2013, 12, 529–534. [CrossRef] [PubMed]
74. Bunting, S.F., Nussenzweig, A. End-joining, translocations and cancer. Nat. Rev. Cancer 2013, 13, 443–454. [CrossRef] [PubMed]
75. Audebert, M., Salles, B., Calsou, P.: Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. J. Biol. Chem. 2004, 279, 55117–55126. [CrossRef] [PubMed]
76. Cuneo, M.J., Gabel, S.A., Krahn, J.M., Ricker, M.A., London, R.E. The structural basis for partitioning of the XRCC1/DNA ligase III-α BRCT-mediated dimer complexes. Nucleic Acids Res. 2011, 39, 7816–7827. [CrossRef] [PubMed]
77. Sfeir, A., Symington, L.S. Microhomology-mediated end joining: A back-up survival mechanismor dedicated pathway? Trends Biochem. Sci. 2015, 40, 701–714. [CrossRef] [PubMed]
78. Czornak, K., Chughtai, S., Chrzanowska, K.H. Mystery of DNA repair: The role of the MRN complex and ATM kinase in DNA damage repair. J. Appl. Genet. 2008, 49, 383–396. [CrossRef] [PubMed]
79. Lamarche, B.J., Orazio, N.I., Weitzman, M.D. The MRN complex in double-strand break repair and telomere maintenance. FEBS Lett. 2010, 584, 3682–3695. [CrossRef] [PubMed]
80. Aravind, L., Makarova, K.S., Koonin, E.V. SURVEY AND SUMMARY: Holliday junction resolvases and related nucleases: Identification of new families, phyletic distribution and evolutionary trajectories. Nucleic Acids Res. 2000, 28, 3417–3432. [CrossRef] [PubMed]
81. Wyatt, H.D.M., West, S.C. Holliday junction resolvases. Cold Spring Harb. Perspect. Biol. 2014, 6, a023192. [CrossRef] [PubMed]
82. Ip, S.C.Y., Rass, U., Blanco, M.G., Flynn, H.R., Skehel, J.M., West, S.C. Identification of Holliday junction resolvases from humans and yeast. Nature 2008, 456, 357–361. [CrossRef] [PubMed]
83. Bizard, A.H., Hickson, I.D. The dissolution of double Holliday junctions. Cold Spring Harb. Perspect. Biol. 2014, 6, a016477. [CrossRef] [PubMed]
84. Swuec, P., Costa, A. Molecular mechanism of double Holliday junction dissolution. Cell Biosci. 2014, 4, 36. [CrossRef] [PubMed]
85. Bocquet, N., Bizard, A.H., Abdulrahman, W., Larsen, N.B., Faty, M., Cavadini, S., Bunker, R.D., Kowalczykowski, S.C., Cejka, P., Hickson, I.D., et al. Structural and mechanistic insight into Holliday-junction dissolution by topoisomerase IIIα and RMI1. Nat. Struct. Mol. Biol. 2014, 21, 261–268. [CrossRef] [PubMed]
86. San Filippo, J., Sung, P., Klein, H. Mechanism of eukaryotic homologous recombination. Annu. Rev. Biochem. 2008, 77, 229–257. [CrossRef] [PubMed]
87. Moynahan, M.E., Jasin, M. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat. Rev. Mol. Cell Biol. 2010, 11, 196–207. [CrossRef] [PubMed]
88. Symington, L.S., Gautier, J.: Double-strand break end resection and repair pathway choice. Annu. Rev. Genet. 2011, 45, 247–271. [CrossRef] [PubMed]
89. Bakr, A., Oing, C., Köcher, S., Borgmann, K., Dornreiter, I., Petersen, C., Dikomey, E., Mansour, W.Y. Involvement of ATM in homologous recombination after end resection and RAD51 nucleofilament formation. Nucleic Acids Res. 2015, 43, 3154–3166. [CrossRef] [PubMed]
90. Dahm-Daphi, J., Hubbe, P., Horvath, F., El-Awady, R.A., Bouffard, K.E., Powell, S.N., Willers, H. Nonhomologous end-joining of site-specific but not of radiation-induced DNA double-strand breaks is reduced in the presence of wild-type p53. Oncogene 2005, 24, 1663–1672. [CrossRef] [PubMed]
91. Menon, V., Povirk, L. Involvement of p53 in the repair of DNA double strand breaks: Multifaceted roles of p53 in homologous recombination repair (HRR) and non-homologous end joining (NHEJ). Subcell. Biochem. 2014, 85, 321–336.[PubMed]
92. Panier, S., Boulton, S.J. Double-strand break repair: 53BP1 comes into focus. Nat. Rev. Mol. Cell Biol. 2014, 15, 7–18. [CrossRef] [PubMed]
93. Bau, D.-T., Mau, Y.-C., Shen, C.-Y. The role of BRCA1 in non-homologous end-joining. Cancer Lett. 2006, 240, 1–8. [CrossRef] [PubMed]
94. Welcsh, P.L., King, M.C. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum. Mol. Genet. 2001, 10, 705–713. [CrossRef] [PubMed]
95. Haupt, S., Raghu, D., Haupt, Y. Mutant p53 drives cancer by subverting multiple tumor suppression pathways. Front. Oncol. 2016, 6, 12. [CrossRef] [PubMed]
96. Guirouilh-Barbat, J., Lambert, S., Bertrand, P., Lopez, B.S. Is homologous recombination really an error-free process? Front. Genet. 2014, 5. [CrossRef] [PubMed]
97. Sharma, S., Javadekar, S.M., Pandey, M., Srivastava, M., Kumari, R., Raghavan, S.C. Homology and enzymatic requirements of microhomology-dependent alternative end joining. Cell Death Dis. 2015, 6, e1697. [CrossRef] [PubMed]
98. Aparicio, T., Baer, R., Gautier, J. DNA double-strand break repair pathway choice and cancer. DNA Repair 2014, 19, 169–175. [CrossRef] [PubMed]
99. Sinha, S., Villarreal, D., Shim, E.Y., Lee, S.E. Risky business: Microhomology-mediated end joining. Mutat. Res. 2016. [CrossRef] [PubMed]
100. Kent, T., Chandramouly, G., McDevitt, S.M., Ozdemir, A.Y., Pomerantz, R.T. Mechanism of microhomology-mediated end-joining promoted by human DNA polymerase θ. Nat. Struct. Mol. Biol. 2015, 22, 230–237. [CrossRef] [PubMed]
101. Lemée, F., Bergoglio, V., Fernandez-Vidal, A., Machado-Silva, A., Pillaire, M.-J., Bieth, A., Gentil, C., Baker, L., Martin, A.-L., Leduc, C., et al. DNA polymerase theta up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instability. Proc. Natl. Acad. Sci. USA 2010, 107, 13390–13395. [CrossRef] [PubMed]
102. Higgins, G.S., Harris, A.L., Prevo, R., Helleday, T., McKenna, W.G., Buffa, F.M. Overexpression of POLQ confers a poor prognosis in early breast cancer patients. Oncotarget 2010, 1, 175–184. [CrossRef] [PubMed]
103. Lee, S.D., Shroyer, K.R., Markham, N.E., Cool, C.D., Voelkel, N.F., Tuder, R.M. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J. Clin. Investig. 1998, 101, 927–934. [CrossRef] [PubMed]
104. Tuder, R.M., Radisavljevic, Z., Shroyer, K.R., Polak, J.M., Voelkel, N.F. Monoclonal endothelial cells in appetite suppressant-associated pulmonary hypertension. Am. J. Respir. Crit. Care Med. 1998, 158, 1999–2001. [CrossRef] [PubMed]
105. Yeager, M.E., Halley, G.R., Golpon, H.A., Voelkel, N.F., Tuder, R.M.: Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ. Res. 2001, 88, E2–E11. [CrossRef] [PubMed]
106. Aldred, M.A., Comhair, S.A., Varella-Garcia, M., Asosingh, K., Xu, W., Noon, G.P., Thistlethwaite, P.A., Tuder, R.M., Erzurum, S.C., Geraci, M.W., et al. Somatic chromosome abnormalities in the lungs of patients with pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2010, 182, 1153–1160. [CrossRef] [PubMed]
107. Federici, C., Drake, K.M., Rigelsky, C.M., McNelly, L.N., Meade, S.L., Comhair, S.A.A., Erzurum, S.C., Aldred, M.A. Increased Mutagen Sensitivity and DNA Damage in Pulmonary Arterial Hypertension. Am. J. Respir. Crit. Care Med. 2015, 192, 219–228. [CrossRef] [PubMed]
108. Simonneau, G., Gatzoulis, M.A., Adatia, I., Celermajer, D., Denton, C., Ghofrani, A., Gomez Sanchez, M.A., Krishna Kumar, R., Landzberg, M., Machado, R.F., et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 2013, 62, D34–D41. [CrossRef] [PubMed]
109. Sanchez, O., Sitbon, O., Jaïs, X., Simonneau, G., Humbert, M. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 2006, 130, 182–189. [CrossRef] [PubMed]
110. Karmochkine, M., Wechsler, B., Godeau, P., Brenot, F., Jagot, J.L., Simonneau, G. Improvement of severe pulmonary hypertension in a patient with SLE. Ann. Rheum. Dis. 1996, 55, 561–562. [CrossRef] [PubMed]
111. Meloche, J., Renard, S., Provencher, S., Bonnet, S.: Anti-inflammatory and immunosuppressive agents in PAH. Handb. Exp. Pharmacol. 2013, 218, 437–476.[PubMed]
112. Jouve, P., Humbert, M., Chauveheid, M.-P., Jaïs, X., Papo, T. POEMS syndrome-related pulmonary hypertension is steroid-responsive. Respir. Med. 2007, 101, 353–355. [CrossRef] [PubMed]
113. Dorfmüller, P., Perros, F., Balabanian, K., Humbert, M. Inflammation in pulmonary arterial hypertension. Eur. Respir. J. 2003, 22, 358–363. [CrossRef] [PubMed]
114. Perros, F., Dorfmüller, P., Montani, D., Hammad, H., Waelput, W., Girerd, B., Raymond, N., Mercier, O., Mussot, S., Cohen-Kaminsky, S., et al. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2012, 185, 311–321. [CrossRef] [PubMed]
115. Cohen-Kaminsky, S., Ranchoux, B., Perros, F. CXCL13 in tertiary lymphoid tissues: Sites of production are different from sites of functional localization. Am. J. Respir. Crit. Care Med. 2014, 189, 369–370. [CrossRef] [PubMed]
116. Price, L.C., Wort, S.J., Perros, F., Dorfmüller, P., Huertas, A., Montani, D., Cohen-Kaminsky, S., Humbert, M. Inflammation in pulmonary arterial hypertension. Chest 2012, 141, 210–221. [CrossRef] [PubMed]
117. Perros, F., Cohen-Kaminsky, S., Gambaryan, N., Girerd, B., Raymond, N., Klingelschmitt, I., Huertas, A., Mercier, O., Fadel, E., Simonneau, G., et al. Cytotoxic cells and granulysin in pulmonary arterial hypertension and pulmonary veno-occlusive disease. Am. J. Respir. Crit. Care Med. 2013, 187, 189–196. [CrossRef] [PubMed]
118. Montani, D., Perros, F., Gambaryan, N., Girerd, B., Dorfmuller, P., Price, L.C., Huertas, A., Hammad, H., Lambrecht, B., Simonneau, G., et al. C-Kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2011, 184, 116–123. [CrossRef] [PubMed]
119. Perros, F., Dorfmüller, P., Souza, R., Durand-Gasselin, I., Mussot, S., Mazmanian, M., Hervé, P., Emilie, D., Simonneau, G., Humbert, M. Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. Eur. Respir. J. 2007, 29, 462–468. [CrossRef] [PubMed]
120. Humbert, M., Monti, G., Brenot, F., Sitbon, O., Portier, A., Grangeot-Keros, L., Duroux, P., Galanaud, P., Simonneau, G., Emilie, D. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am. J. Respir. Crit. Care Med. 1995, 151, 1628–1631. [CrossRef] [PubMed]
121. Soon, E., Holmes, A.M., Treacy, C.M., Doughty, N.J., Southgate, L., Machado, R.D., Trembath, R.C., Jennings, S., Barker, L., Nicklin, P., et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 2010, 122, 920–927. [CrossRef] [PubMed]
122. Hautefort, A., Girerd, B., Montani, D., Cohen-Kaminsky, S., Price, L., Lambrecht, B.N., Humbert, M., Perros, F. T-helper 17 cell polarization in pulmonary arterial hypertension. Chest 2015, 147, 1610–1620. [CrossRef] [PubMed]
123. Itoh, T., Nagaya, N., Ishibashi-Ueda, H., Kyotani, S., Oya, H., Sakamaki, F., Kimura, H., Nakanishi, N. Increased plasma monocyte chemoattractant protein-1 level in idiopathic pulmonary arterial hypertension. Respirology 2006, 11, 158–163. [CrossRef] [PubMed]
124. Golembeski, S.M., West, J., Tada, Y., Fagan, K.A. Interleukin-6 causes mild pulmonary hypertension and augments hypoxia-induced pulmonary hypertension in mice. Chest 2005, 128, 572S–573S. [CrossRef] [PubMed]
125. Miyata, M., Sakuma, F., Yoshimura, A., Ishikawa, H., Nishimaki, T., Kasukawa, R. Pulmonary hypertension in rats. 2. Role of interleukin-6. Int. Arch. Allergy Immunol. 1995, 108, 287–291. [CrossRef] [PubMed]
126. Steiner, M.K., Syrkina, O.L., Kolliputi, N., Mark, E.J., Hales, C.A., Waxman, A.B. Interleukin-6 overexpression induces pulmonary hypertension. Circ. Res. 2009, 104, 236–244. [CrossRef] [PubMed]
127. Savale, L., Tu, L., Rideau, D., Izziki, M., Maitre, B., Adnot, S., Eddahibi, S. Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir. Res. 2009, 10, 6. [CrossRef] [PubMed]
128. Meira, L.B., Bugni, J.M., Green, S.L., Lee, C.-W., Pang, B., Borenshtein, D., Rickman, B.H., Rogers, A.B., Moroski-Erkul, C.A., McFaline, J.L., et al. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J. Clin. Investig. 2008, 118, 2516–2525. [CrossRef] [PubMed]
129. Wheelhouse, N.M., Chan, Y.-S., Gillies, S.E., Caldwell, H., Ross, J.A., Harrison, D.J., Prost, S.: TNF-α induced DNA damage in primary murine hepatocytes. Int. J. Mol. Med. 2003, 12, 889–894. [CrossRef] [PubMed]
130. Suematsu, N., Tsutsui, H., Wen, J., Kang, D., Ikeuchi, M., Ide, T., Hayashidani, S., Shiomi, T., Kubota, T., Hamasaki, N., et al. Oxidative stress mediates tumor necrosis factor-alpha-induced mitochondrial DNA damage and dysfunction in cardiac myocytes. Circulation 2003, 107, 1418–1423. [CrossRef] [PubMed]
131. Poltz, R., Naumann, M. Dynamics of p53 and NF-κB regulation in response to DNA damage and identification of target proteins suitable for therapeutic intervention. BMC Syst. Biol. 2012, 6, 125. [CrossRef] [PubMed]
132. Pikarsky, E., Porat, R.M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich-Pyest, E., Urieli-Shoval, S., Galun, E., Ben-Neriah, Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431, 461–466. [CrossRef] [PubMed]
133. Kidane, D., Chae, W.J., Czochor, J., Eckert, K.A., Glazer, P.M., Bothwell, A.L.M., Sweasy, J.B. Interplay between DNA repair and inflammation, and the link to cancer. Crit. Rev. Biochem. Mol. Biol. 2014, 49, 116–139. [CrossRef] [PubMed]
134. Hussain, S.P., Harris, C.C. Inflammation and cancer: An ancient link with novel potentials. Int. J. Cancer 2007, 121, 2373–2380. [CrossRef] [PubMed]
135. Schetter, A.J., Heegaard, N.H.H., Harris, C.C. Inflammation and cancer: Interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 2010, 31, 37–49. [CrossRef] [PubMed]
136. Pálmai-Pallag, T., Bachrati, C.Z.: Inflammation-induced DNA damage and damage-induced inflammation: A vicious cycle. Microbes Infect. Inst. Pasteur 2014, 16, 822–832. [CrossRef] [PubMed]
137. Olivieri, F., Albertini, M.C., Orciani, M., Ceka, A., Cricca, M., Procopio, A.D., Bonafè, M.: DNA damage response (DDR) and senescence: Shuttled inflamma-miRNAs on the stage of inflamm-aging. Oncotarget 2015, 6, 35509–35521.[PubMed]
138. Yun, U.J., Park, S.E., Jo, Y.S., Kim, J., Shin, D.Y. DNA damage induces the IL-6/STAT3 signaling pathway, which has anti-senescence and growth-promoting functions in human tumors. Cancer Lett. 2012, 323, 155–160. [CrossRef] [PubMed]
139. Grivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.-Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L., et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15, 103–113. [CrossRef] [PubMed]
140. Bromberg, J., Wang, T.C. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 2009, 15, 79–80. [CrossRef] [PubMed]
141. Morrell, N.W. Pulmonary hypertension due to BMPR2 mutation: A new paradigm for tissue remodeling? Proc. Am. Thorac. Soc. 2006, 3, 680–686. [CrossRef] [PubMed]
142. Hagen, M., Fagan, K., Steudel, W., Carr, M., Lane, K., Rodman, D.M., West, J. Interaction of interleukin-6 and the BMP pathway in pulmonary smooth muscle. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007, 292, L1473–L1479. [CrossRef] [PubMed]
143. Perros, F., Bonnet, S.: Bone morphogenetic protein receptor type II and inflammation are bringing old concepts into the new pulmonary arterial hypertension world. Am. J. Respir. Crit. Care Med. 2015, 192, 777–779. [CrossRef] [PubMed]
144. Soon, E., Crosby, A., Southwood, M., Yang, P., Tajsic, T., Toshner, M., Appleby, S., Shanahan, C.M., Bloch, K.D., Pepke-Zaba, J., et al. Bone morphogenetic protein receptor type II deficiency and increased inflammatory cytokine production. A gateway to pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2015, 192, 859–872. [CrossRef] [PubMed]
145. Paulin, R., Meloche, J., Bonnet, S. STAT3 signaling in pulmonary arterial hypertension. JAK-STAT 2012, 1, 223–233. [CrossRef] [PubMed]
146. Perros, F., Montani, D., Dorfmüller, P., Durand-Gasselin, I., Tcherakian, C., Le Pavec, J., Mazmanian, M., Fadel, E., Mussot, S., Mercier, O., et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2008, 178, 81–88. [CrossRef] [PubMed]
147. Aggarwal, S., Gross, C.M., Sharma, S., Fineman, J.R., Black, S.M. Reactive oxygen species in pulmonary vascular remodeling. Compr. Physiol. 2013, 3, 1011–1034.[PubMed]
148. Bowers, R., Cool, C., Murphy, R.C., Tuder, R.M., Hopken, M.W., Flores, S.C., Voelkel, N.F. Oxidative stress in severe pulmonary hypertension. Am. J. Respir. Crit. Care Med. 2004, 169, 764–769. [CrossRef] [PubMed]
149. Demarco, V.G., Whaley-Connell, A.T., Sowers, J.R., Habibi, J., Dellsperger, K.C. Contribution of oxidative stress to pulmonary arterial hypertension. World J. Cardiol. 2010, 2, 316–324. [CrossRef] [PubMed]
150. Dorfmüller, P., Chaumais, M.-C., Giannakouli, M., Durand-Gasselin, I., Raymond, N., Fadel, E., Mercier, O., Charlotte, F., Montani, D., Simonneau, G., et al. Increased oxidative stress and severe arterial remodeling induced by permanent high-flow challenge in experimental pulmonary hypertension. Respir. Res. 2011, 12, 119. [CrossRef] [PubMed]
151. Black, S.M., DeVol, J.M., Wedgwood, S. Regulation of fibroblast growth factor-2 expression in pulmonary arterial smooth muscle cells involves increased reactive oxygen species generation. Am. J. Physiol. Cell Physiol. 2008, 294, C345–C354. [CrossRef] [PubMed]
152. 2 increases expression of pulmonary artery endothelial cell platelet-derived growth factor mRNA. J. Appl. Physiol. 1992, 73, 2255–2262.[PubMed]
153. Wedgwood, S., Dettman, R.W., Black, S.M. ET-1 stimulates pulmonary arterial smooth muscle cell proliferation via induction of reactive oxygen species. Am. J. Physiol. Lung Cell. Mol. Physiol. 2001, 281, L1058–1067.[PubMed]
154. Block, K., Gorin, Y., Hoover, P., Williams, P., Chelmicki, T., Clark, R.A., Yoneda, T., Abboud, H.E. NAD(P)H oxidases regulate HIF-2alpha protein expression. J. Biol. Chem. 2007, 282, 8019–8026. [CrossRef] [PubMed]
155. 2 SENSING. J. Biol. Chem. 2000, 275, 25130–25138. [CrossRef] [PubMed]
156. Gale, D.P., Harten, S.K., Reid, C.D.L., Tuddenham, E.G.D., Maxwell, P.H. Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2α mutation. Blood 2008, 112, 919–921. [CrossRef] [PubMed]
157. Brusselmans, K., Compernolle, V., Tjwa, M., Wiesener, M.S., Maxwell, P.H., Collen, D., Carmeliet, P. Heterozygous deficiency of hypoxia-inducible factor–2α protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. J. Clin. Investig. 2003, 111, 1519–1527. [CrossRef] [PubMed]
158. Cheng, T.H., Shih, N.L., Chen, S.Y., Loh, S.H., Cheng, P.Y., Tsai, C.S., Liu, S.H., Wang, D.L., Chen, J.J. Reactive oxygen species mediate cyclic strain-induced endothelin-1 gene expression via Ras/Raf/extracellular signal-regulated kinase pathway in endothelial cells. J. Mol. Cell. Cardiol. 2001, 33, 1805–1814. [CrossRef] [PubMed]
159. Tate, R.M., Morris, H.G., Schroeder, W.R., Repine, J.E. Oxygen metabolites stimulate thromboxane production and vasoconstriction in isolated saline-perfused rabbit lungs. J. Clin. Investig. 1984, 74, 608–613. [CrossRef] [PubMed]
160. Lee, D.S., McCallum, E.A., Olson, D.M. Effects of reactive oxygen species on prostacyclin production in perinatal rat lung cells. J. Appl. Physiol. 1989, 66, 1321–1327.[PubMed]
161. Brito, R., Castillo, G., González, J., Valls, N., Rodrigo, R. Oxidative stress in hypertension: Mechanisms and therapeutic opportunities. Exp. Clin. Endocrinol. Diabetes 2015, 123, 325–335. [CrossRef] [PubMed]
162. Weissmann, N., Winterhalder, S., Nollen, M., Voswinckel, R., Quanz, K., Ghofrani, H.A., Schermuly, R.T., Seeger, W., Grimminger, F. NO and reactive oxygen species are involved in biphasic hypoxic vasoconstriction of isolated rabbit lungs. Am. J. Physiol. Lung Cell. Mol. Physiol. 2001, 280, L638–L645.[PubMed]
163. Waypa, G.B., Marks, J.D., Mack, M.M., Boriboun, C., Mungai, P.T., Schumacker, P.T. Mitochondrial Reactive oxygen species trigger calcium increases during hypoxia in pulmonary arterial myocytes. Circ. Res. 2002, 91, 719–726. [CrossRef] [PubMed]
164. Hoshikawa, Y., Ono, S., Suzuki, S., Tanita, T., Chida, M., Song, C., Noda, M., Tabata, T., Voelkel, N.F., Fujimura, S. Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia. J. Appl. Physiol. 2001, 90, 1299–1306.[PubMed]
165. Jankov, R.P., Kantores, C., Pan, J., Belik, J. Contribution of xanthine oxidase-derived superoxide to chronic hypoxic pulmonary hypertension in neonatal rats. Am. J. Physiol. 2008, 294, L233–L245. [CrossRef] [PubMed]
166. Rafikova, O., Rafikov, R., Kangath, A., Qu, N., Aggarwal, S., Sharma, S., Desai, J., Fields, T., Ludewig, B., Yuan, J.X.-Y., et al. Redox regulation of epidermal growth factor receptor signaling during the development of pulmonary hypertension. Free Radic. Biol. Med. 2016. [CrossRef] [PubMed]
167. Rawat, D.K., Alzoubi, A., Gupte, R., Chettimada, S., Watanabe, M., Kahn, A.G., Okada, T., McMurtry, I.F., Gupte, S.A.: Increased reactive oxygen species, metabolic maladaptation, and autophagy contribute to pulmonary arterial hypertension-induced ventricular hypertrophy and diastolic heart failure. Hypertension 2014, 64, 1266–1274. [CrossRef] [PubMed]
168. Liu, J.Q., Zelko, I.N., Erbynn, E.M., Sham, J.S.K., Folz, R.J. Hypoxic pulmonary hypertension: Role of superoxide and NADPH oxidase (gp91phox). Am. J. Physiol. Lung Cell. Mol. Physiol. 2006, 290, L2–L10. [CrossRef] [PubMed]
169. Matsui, H., Shimosawa, T., Itakura, K., Guanqun, X., Ando, K., Fujita, T. Adrenomedullin can protect against pulmonary vascular remodeling induced by hypoxia. Circulation 2004, 109, 2246–2251. [CrossRef] [PubMed]
170. Liu, M., Wang, Y., Zheng, L., Zheng, W., Dong, K., Chen, S., Zhang, B., Li, Z. Fasudil reversed MCT-induced and chronic hypoxia-induced pulmonary hypertension by attenuating oxidative stress and inhibiting the expression of Trx1 and HIF-1α. Respir. Physiol. Neurobiol. 2014, 201, 38–46. [CrossRef] [PubMed]
171. Zhang, B., Niu, W., Xu, D., Li, Y., Liu, M., Wang, Y., Luo, Y., Zhao, P., Liu, Y., Dong, M., et al. Oxymatrine prevents hypoxia- and monocrotaline-induced pulmonary hypertension in rats. Free Radic. Biol. Med. 2014, 69, 198–207. [CrossRef] [PubMed]
172. Chaumais, M.-C., Ranchoux, B., Montani, D., Dorfmüller, P., Tu, L., Lecerf, F., Raymond, N., Guignabert, C., Price, L., Simonneau, G., et al. N-acetylcysteine improves established monocrotaline-induced pulmonary hypertension in rats. Respir. Res. 2014, 15, 65. [CrossRef] [PubMed]
173. Mittal, M., Roth, M., König, P., Hofmann, S., Dony, E., Goyal, P., Selbitz, A.-C., Schermuly, R.T., Ghofrani, H.A., Kwapiszewska, G., et al. Hypoxia-dependent regulation of nonphagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature. Circ. Res. 2007, 101, 258–267. [CrossRef] [PubMed]
174. Babior, B.M. The NADPH oxidase of endothelial cells. IUBMB Life 2000, 50, 267–269. [CrossRef] [PubMed]
175. Vignais, P.V. The superoxide-generating NADPH oxidase: Structural aspects and activation mechanism. Cell. Mol. Life Sci. 2002, 59, 1428–1459. [CrossRef] [PubMed]
176. Fresquet, F., Pourageaud, F., Leblais, V., Brandes, R.P., Savineau, J.-P., Marthan, R., Muller, B. Role of reactive oxygen species and gp91phox in endothelial dysfunction of pulmonary arteries induced by chronic hypoxia. Br. J. Pharmacol. 2006, 148, 714–723. [CrossRef] [PubMed]
177. Paravicini, T.M., Gulluyan, L.M., Dusting, G.J., Drummond, G.R.: Increased NADPH oxidase activity, gp91phox expression, and endothelium-dependent vasorelaxation during neointima formation in rabbits. Circ. Res. 2002, 91, 54–61. [CrossRef] [PubMed]
178. Li, S., Tabar, S.S., Malec, V., Eul, B.G., Klepetko, W., Weissmann, N., Grimminger, F., Seeger, W., Rose, F., Hänze, J. NOX4 regulates ROS levels under normoxic and hypoxic conditions, triggers proliferation, and inhibits apoptosis in pulmonary artery adventitial fibroblasts. Antioxid. Redox Signal. 2008, 10, 1687–1698. [CrossRef] [PubMed]
179. Sturrock, A., Cahill, B., Norman, K., Huecksteadt, T.P., Hill, K., Sanders, K., Karwande, S.V., Stringham, J.C., Bull, D.A., Gleich, M., et al. Transforming growth factor-beta1 induces Nox4 NAD(P)H oxidase and reactive oxygen species-dependent proliferation in human pulmonary artery smooth muscle cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2006, 290, L661–L673. [CrossRef] [PubMed]
180. Selimovic, N., Bergh, C.-H., Andersson, B., Sakiniene, E., Carlsten, H., Rundqvist, B. Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension. Eur. Respir. J. 2009, 34, 662–668. [CrossRef] [PubMed]
181. Landmesser, U., Dikalov, S., Price, S.R., McCann, L., Fukai, T., Holland, S.M., Mitch, W.E., Harrison, D.G. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J. Clin. Investig. 2003, 111, 1201–1209. [CrossRef] [PubMed]
182. Morris, C.R., Kato, G.J., Poljakovic, M., Wang, X., Blackwelder, W.C., Sachdev, V., Hazen, S.L., Vichinsky, E.P., Morris, S.M., Gladwin, M.T. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA 2005, 294, 81–90. [CrossRef] [PubMed]
183. Pullamsetti, S., Kiss, L., Ghofrani, H.A., Voswinckel, R., Haredza, P., Klepetko, W., Aigner, C., Fink, L., Muyal, J.P., Weissmann, N., et al. Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2005, 19, 1175–1177. [CrossRef]
184. Iannone, L., Zhao, L., Dubois, O., Duluc, L., Rhodes, C.J., Wharton, J., Wilkins, M.R., Leiper, J., Wojciak-Stothard, B. miR-21/DDAH1 pathway regulates pulmonary vascular responses to hypoxia. Biochem. J. 2014, 462, 103–112. [CrossRef] [PubMed]
185. Li, X.-H., Peng, J., Tan, N., Wu, W.-H., Li, T.-T., Shi, R.-Z., Li, Y.-J. Involvement of asymmetric dimethylarginine and Rho kinase in the vascular remodeling in monocrotaline-induced pulmonary hypertension. Vascul. Pharmacol. 2010, 53, 223–229. [CrossRef] [PubMed]
186. Archer, S.L., Marsboom, G., Kim, G.H., Zhang, H.J., Toth, P.T., Svensson, E.C., Dyck, J.R.B., Gomberg-Maitland, M., Thébaud, B., Husain, A.N., et al. Epigenetic attenuation of mitochondrial superoxide dismutase 2 (SOD2) in pulmonary arterial hypertension. Circulation 2010, 121, 2661–2671. [CrossRef] [PubMed]
187. Reis, G.S., Augusto, V.S., Silveira, A.P.C., Jordão, A.A., Baddini-Martinez, J., Poli Neto, O., Rodrigues, A.J., Evora, P.R.B. Oxidative-stress biomarkers in patients with pulmonary hypertension. Pulm. Circ. 2013, 3, 856–861. [CrossRef] [PubMed]
188. Cracowski, J.L., Cracowski, C., Bessard, G., Pepin, J.L., Bessard, J., Schwebel, C., Stanke-Labesque, F., Pison, C. Increased lipid peroxidation in patients with pulmonary hypertension. Am. J. Respir. Crit. Care Med. 2001, 164, 1038–1042. [CrossRef] [PubMed]
189. Wong, C.-M., Bansal, G., Pavlickova, L., Marcocci, L., Suzuki, Y.J. Reactive oxygen species and antioxidants in pulmonary hypertension. Antioxid. Redox Signal. 2013, 18, 1789–1796. [CrossRef] [PubMed]
190. Tabima, D.M., Frizzell, S., Gladwin, M.T. Reactive oxygen and nitrogen species in pulmonary hypertension. Free Radic. Biol. Med. 2012, 52, 1970–1986. [CrossRef] [PubMed]
191. Crosswhite, P., Sun, Z. Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension. J. Hypertens. 2010, 28, 201–212. [CrossRef] [PubMed]
192. Yasui, M., Kanemaru, Y., Kamoshita, N., Suzuki, T., Arakawa, T., Honma, M. Tracing the fates of site-specifically introduced DNA adducts in the human genome. DNA Repair 2014, 15, 11–20. [CrossRef] [PubMed]
193. Martinez, G.R., Loureiro, A.P.M., Marques, S.A., Miyamoto, S., Yamaguchi, L.F., Onuki, J., Almeida, E.A., Garcia, C.C.M., Barbosa, L.F., Medeiros, M.H.G., et al. Oxidative and alkylating damage in DNA. Mutat. Res. 2003, 544, 115–127. [CrossRef] [PubMed]
194. Klaunig, J.E., Kamendulis, L.M., Hocevar, B.A. Oxidative stress and oxidative damage in carcinogenesis. Toxicol. Pathol. 2010, 38, 96–109. [CrossRef] [PubMed]
195. Gurtner, H.P. Aminorex and pulmonary hypertension. A review. Cor et Vasa 1985, 27, 160–171.[PubMed]
196. Simonneau, G., Fartoukh, M., Sitbon, O., Humbert, M., Jagot, J.L., Hervé, P. Primary pulmonary hypertension associated with the use of fenfluramine derivatives. Chest 1998, 114, 195S–199S. [CrossRef] [PubMed]
197. Douglas, J.G., Munro, J.F., Kitchin, A.H., Muir, A.L., Proudfoot, A.T.: Pulmonary hypertension and fenfluramine. Br. Med. J. Clin. Res. Ed. 1981, 283, 881–883. [CrossRef] [PubMed]
198. Sitbon, O., Humbert, M., Simonneau, G. Pulmonary hypertension related to appetite suppressants. In Pulmonary Circulation: Diseases and Their Treatment, 3rd ed., CRC Press: Boca Raton, FL, USA, 2011.
199. Chin, K.M., Channick, R.N., Rubin, L.J. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest 2006, 130, 1657–1663. [CrossRef] [PubMed]
200. Schaiberger, P.H., Kennedy, T.C., Miller, F.C., Gal, J., Petty, T.L. Pulmonary hypertension associated with long-term inhalation of “crank” methamphetamine. Chest 1993, 104, 614–616. [CrossRef] [PubMed]
201. Montani, D., Seferian, A., Savale, L., Simonneau, G., Humbert, M. Drug-induced pulmonary arterial hypertension: A recent outbreak. Eur. Respir. Rev. 2013, 22, 244–250. [CrossRef] [PubMed]
202. Gonçalves, C.L., Rezin, G.T., Ferreira, G.K., Jeremias, I.C., Cardoso, M.R., Valvassori, S.S., Munhoz, B.J.P., Borges, G.D., Bristot, B.N., Leffa, D.D., et al. Effects of acute and chronic administration of fenproporex on DNA damage parameters in young and adult rats. Mol. Cell. Biochem. 2013, 380, 171–176. [CrossRef] [PubMed]
203. Alvarenga, T.A., Andersen, M.L., Ribeiro, D.A., Araujo, P., Hirotsu, C., Costa, J.L., Battisti, M.C., Tufik, S. Single exposure to cocaine or ecstasy induces DNA damage in brain and other organs of mice. Addict. Biol. 2010, 15, 96–99. [CrossRef] [PubMed]
204. Andreazza, A.C., Kauer-Sant’Anna, M., Frey, B.N., Stertz, L., Zanotto, C., Ribeiro, L., Giasson, K., Valvassori, S.S., Réus, G.Z., Salvador, M., et al. Effects of mood stabilizers on DNA damage in an animal model of mania. J. Psychiatry Neurosci. 2008, 33, 516–524.[PubMed]
205. Agarwal, K., Mukherjee, A., Sharma, A., Sharma, R., Bhardwaj, K.R., Sen, S. Clastogenic effect of fenfluramine in mice bone marrow cells in vivo. Environ. Mol. Mutagen. 1992, 19, 323–326. [CrossRef] [PubMed]
206. Johnson, Z., Venters, J., Guarraci, F.A., Zewail-Foote, M. Methamphetamine induces DNA damage in specific regions of the female rat brain. Clin. Exp. Pharmacol. Physiol. 2015, 42, 570–575. [CrossRef] [PubMed]
207. Nakagawa, Y., Tayama, S., Ogata, A., Suzuki, T., Ishii, H. ATP-generating glycolytic substrates prevent N-nitrosofenfluramine-induced cytotoxicity in isolated rat hepatocytes. Chem. Biol. Interact. 2006, 164, 93–101. [CrossRef] [PubMed]
208. Parolini, M., Magni, S., Castiglioni, S., Binelli, A. Amphetamine exposure imbalanced antioxidant activity in the bivalve Dreissena polymorpha causing oxidative and genetic damage. Chemosphere 2016, 144, 207–213. [CrossRef] [PubMed]
209. Da Silva, C.J., dos Santos, J.E., Satie Takahashi, C. An evaluation of the genotoxic and cytotoxic effects of the anti-obesity drugs sibutramine and fenproporex. Hum. Exp. Toxicol. 2010, 29, 187–197. [CrossRef] [PubMed]
210. Perfeito, R., Cunha-Oliveira, T., Rego, A.C. Reprint of: Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse. Free Radic. Biol. Med. 2013, 62, 186–201. [CrossRef] [PubMed]
211. Bengel, D., Isaacs, K.R., Heils, A., Lesch, K.P., Murphy, D.L. The appetite suppressant d-fenfluramine induces apoptosis in human serotonergic cells. Neuroreport 1998, 9, 2989–2993. [CrossRef] [PubMed]
212. Eddahibi, S., Adnot, S. Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: Lessons for the future in pathogenesis. Respir. Res. 2002, 3, 9. [CrossRef] [PubMed]
213. Alwan, S., Bandoli, G., Chambers, C.D. Maternal use of selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. Clin. Pharmacol. Ther. 2016. [CrossRef] [PubMed]
214. Fornaro, E., Li, D., Pan, J., Belik, J. Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat. Am. J. Respir. Crit. Care Med. 2007, 176, 1035–1040. [CrossRef] [PubMed]
215. Sadoughi, A., Roberts, K.E., Preston, I.R., Lai, G.P., McCollister, D.H., Farber, H.W., Hill, N.S. Use of selective serotonin reuptake inhibitors and outcomes in pulmonary arterial hypertension. Chest 2013, 144, 531–541. [CrossRef] [PubMed]
216. Dhalla, I.A., Juurlink, D.N., Gomes, T., Granton, J.T., Zheng, H., Mamdani, M.M. Selective serotonin reuptake inhibitors and pulmonary arterial hypertension: A case-control study. Chest 2012, 141, 348–353. [CrossRef] [PubMed]
217. Eddahibi, S., Humbert, M., Fadel, E., Raffestin, B., Darmon, M., Capron, F., Simonneau, G., Dartevelle, P., Hamon, M., Adnot, S. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J. Clin. Investig. 2001, 108, 1141–1150. [CrossRef] [PubMed]
218. Eddahibi, S., Hanoun, N., Lanfumey, L., Lesch, K.P., Raffestin, B., Hamon, M., Adnot, S. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J. Clin. Investig. 2000, 105, 1555–1562. [CrossRef] [PubMed]
219. Gürbüzel, M., Oral, E., Kizilet, H., Halici, Z., Gulec, M.: Genotoxic evaluation of selective serotonin-reuptake inhibitors by use of the somatic mutation and recombination test in Drosophila melanogaster. Mutat. Res. 2012, 748, 17–20. [CrossRef] [PubMed]
220. Djordjevic, J., Djordjevic, A., Adzic, M., Elaković, I., Matić, G., Radojcic, M.B. Fluoxetine affects antioxidant system and promotes apoptotic signaling inWistar rat liver. Eur. J. Pharmacol. 2011, 659, 61–66. [CrossRef] [PubMed]
221. Alzahrani, H.A.S. Sister chromatid exchanges and sperm abnormalities produced by antidepressant drug fluoxetine in mouse treated in vivo. Eur. Rev. Med. Pharmacol. Sci. 2012, 16, 2154–2161.[PubMed]
222. Riggin, L., Koren, G. Effects of selective serotonin reuptake inhibitors on sperm and male fertility. Can. Fam. Physician 2015, 61, 529–530.
223. Attia, S.M., Bakheet, S.A. Citalopram at the recommended human doses after long-term treatment is genotoxic for male germ cell. Food Chem. Toxicol. Int. J. Publ. Br. Ind. Biol. Res. Assoc. 2013, 53, 281–285. [CrossRef] [PubMed]
224. Tanrikut, C., Feldman, A.S., Altemus, M., Paduch, D.A., Schlegel, P.N. Adverse effect of paroxetine on sperm. Fertil. Steril. 2010, 94, 1021–1026. [CrossRef] [PubMed]
225. Fox, B.D., Azoulay, L., Dell’Aniello, S., Langleben, D., Lapi, F., Benisty, J., Suissa, S. The use of antidepressants and the risk of idiopathic pulmonary arterial hypertension. Can. J. Cardiol. 2014, 30, 1633–1639. [CrossRef] [PubMed]
226. Czarny, P., Kwiatkowski, D., Kacperska, D., Kawczyńska, D., Talarowska, M., Orzechowska, A., Bielecka-Kowalska, A., Szemraj, J., Gałecki, P., Śliwiński, T. Elevated level of DNA damage and impaired repair of oxidative DNA damage in patients with recurrent depressive disorder. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 2015, 21, 412–418.
227. Black, C.N., Bot, M., Scheffer, P.G., Cuijpers, P., Penninx, B.W.J.H. Is depression associated with increased oxidative stress? A systematic review and meta-analysis. Psychoneuroendocrinology 2015, 51, 164–175. [CrossRef] [PubMed]
228. Lacave, R., Larsen, C.-J., Robert, J. Cancérologie Fondamentale, John Libbey Eurotext: Paris, France, 2005.
229. Kondo, N., Takahashi, A., Ono, K., Ohnishi, T. DNA damage induced by alkylating agents and repair pathways. J. Nucleic Acids 2010, 2010, 543531. [CrossRef] [PubMed]
230. Fu, D., Calvo, J.A., Samson, L.D. Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat. Rev. Cancer 2012, 12, 104–120. [CrossRef] [PubMed]
231. Hoorn, C.M., Wagner, J.G., Petry, T.W., Roth, R.A. Toxicity of mitomycin C toward cultured pulmonary artery endothelium. Toxicol. Appl. Pharmacol. 1995, 130, 87–94. [CrossRef] [PubMed]
232. Lushnikova, E.L., Molodykh, O.P., Nepomnyashchikh, L.M., Bakulina, A.A., Sorokina, Y.A. Ultrastructurural picture of cyclophosphamide-induced damage to the liver. Bull. Exp. Biol. Med. 2011, 151, 751–756. [CrossRef] [PubMed]
233. Ranchoux, B., Günther, S., Quarck, R., Chaumais, M.-C., Dorfmüller, P., Antigny, F., Dumas, S.J., Raymond, N., Lau, E., Savale, L., et al. Chemotherapy-induced pulmonary hypertension: Role of alkylating agents. Am. J. Pathol. 2015, 185, 356–371. [CrossRef] [PubMed]
234. Perros, F., Günther, S., Ranchoux, B., Godinas, L., Antigny, F., Chaumais, M.-C., Dorfmüller, P., Hautefort, A., Raymond, N., Savale, L., et al. Mitomycin-induced pulmonary veno-occlusive disease: Evidence from human disease and animal models. Circulation 2015, 132, 834–847. [CrossRef] [PubMed]
235. Montani, D., Lau, E.M., Dorfmüller, P., Girerd, B., Jaïs, X., Savale, L., Perros, F., Nossent, E., Garcia, G., Parent, F., et al. Pulmonary veno-occlusive disease. Eur. Respir. J. 2016, 47, 1518–1534. [CrossRef] [PubMed]
236. Siegel, D., Franklin, W.A., Ross, D. Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors. Clin. Cancer Res. 1998, 4, 2065–2070.[PubMed]
237. Cooper, J.A., Merrill, W.W., Reynolds, H.Y. Cyclophosphamide modulation of bronchoalveolar cellular populations and macrophage oxidative metabolism. Possible mechanisms of pulmonary pharmacotoxicity. Am. Rev. Respir. Dis. 1986, 134, 108–114.[PubMed]
238. Hamano, Y., Sugimoto, H., Soubasakos, M.A., Kieran, M., Olsen, B.R., Lawler, J., Sudhakar, A., Kalluri, R. Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res. 2004, 64, 1570–1574. [CrossRef] [PubMed]
239. Ohtani, T., Nakamura, T., Toda, K.-I., Furukawa, F. Cyclophosphamide enhances TNF-α-induced apoptotic cell death in murine vascular endothelial cell. FEBS Lett. 2006, 580, 1597–1600. [CrossRef] [PubMed]
240. Mytilineou, C., Kramer, B.C., Yabut, J.A.: Glutathione depletion and oxidative stress. Parkinsonism Relat. Disord. 2002, 8, 385–387. [CrossRef]
241. Srivastava, A., Poonkuzhali, B., Shaji, R.V., George, B., Mathews, V., Chandy, M., Krishnamoorthy, R. Glutathione S-transferase M1 polymorphism: A risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood 2004, 104, 1574–1577. [CrossRef] [PubMed]
242. DeLeve, L.D.: Cellular target of cyclophosphamide toxicity in the murine liver: Role of glutathione and site of metabolic activation. Hepatology 1996, 24, 830–837. [CrossRef] [PubMed]
243. Montani, D., Lau, E.M., Descatha, A., Jaïs, X., Savale, L., Andujar, P., Bensefa-Colas, L., Girerd, B., Zendah, I., Le Pavec, J., et al. Occupational exposure to organic solvents: A risk factor for pulmonary veno-occlusive disease. Eur. Respir. J. 2015, 46, 1721–1731. [CrossRef] [PubMed]
244. Hu, C., Jiang, L., Geng, C., Zhang, X., Cao, J., Zhong, L. Possible involvement of oxidative stress in trichloroethylene-induced genotoxicity in human HepG2 cells. Mutat. Res. 2008, 652, 88–94. [CrossRef] [PubMed]
245. Roth, R.A., Reindel, J.F. Lung vascular injury from monocrotaline pyrrole, a putative hepatic metabolite. Adv. Exp. Med. Biol. 1991, 283, 477–487.[PubMed]
246. Yan, C.C., Huxtable, R.J. Release of an alkylating metabolite, dehydromonocrotaline, from the isolated liver perfused with the pyrrolizidine alkaloid, monocrotaline. Proc. West. Pharmacol. Soc. 1994, 37, 107–108.[PubMed]
247. Mattocks, A.R., Jukes, R. Trapping and measurement of short-lived alkylating agents in a recirculating flow system. Chem. Biol. Interact. 1990, 76, 19–30. [CrossRef]
248. Meloche, J., Pflieger, A., Vaillancourt, M., Paulin, R., Potus, F., Zervopoulos, S., Graydon, C., Courboulin, A., Breuils-Bonnet, S., Tremblay, E., et al. Role for DNA damage signaling in pulmonary arterial hypertension. Circulation 2014, 129, 786–797. [CrossRef] [PubMed]
249. Meloche, J., Le Guen, M., Potus, F., Vinck, J., Ranchoux, B., Johnson, I., Antigny, F., Tremblay, E., Breuils-Bonnet, S., Perros, F., et al. miR-223 reverses experimental pulmonary arterial hypertension. Am. J. Physiol. Cell Physiol. 2015, 309, C363–C372. [CrossRef] [PubMed]
250. Zhong, Z., Wen, Z., Darnell, J.E. Stat3: A STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994, 264, 95–98. [CrossRef] [PubMed]
251. Meloche, J.; Potus, F.; Vaillancourt, M.; Bourgeois, A.; Johnson, I.; Deschamps, L.; Chabot, S.; Ruffenach, G.; Henry, S.; Breuils-Bonnet, S. et al. Bromodomain-containing protein 4: The epigenetic origin of pulmonary arterial hypertension. Circ. Res. 2015, 117, 525–535.[CrossRef] [PubMed]
252. Wang, M.; Wu, W.; Wu, W.; Rosidi, B.; Zhang, L.; Wang, H.; Iliakis, G. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res. 2006, 34, 6170–6182.[CrossRef] [PubMed]
253. Byrne, M.; Wray, J.; Reinert, B.; Wu, Y.; Nickoloff, J.; Lee, S.-H.; Hromas, R.; Williamson, E. Mechanisms of oncogenic chromosomal translocations. Ann. N. Y. Acad. Sci. 2014, 1310, 89–97.[CrossRef] [PubMed]
254. Wray, J.; Williamson, E.A.; Singh, S.B.; Wu, Y.; Cogle, C.R.; Weinstock, D.M.; Zhang, Y.; Lee, S.-H.; Zhou, D.; Shao, L. et al. PARP1 is required for chromosomal translocations. Blood 2013, 121, 4359–4365.[CrossRef] [PubMed]
255. Soni, A.; Siemann, M.; Grabos, M.; Murmann, T.; Pantelias, G.E.; Iliakis, G. Requirement for Parp-1 and DNA ligases 1 or 3 but not of Xrcc1 in chromosomal translocation formation by backup end joining. Nucleic Acids Res. 2014, 42, 6380–6392.[CrossRef] [PubMed]
256. Kumar, R. Nuclear Signaling Pathways and Targeting Transcription in Cancer; Springer Science & Business Media: New York, NY, USA, 2013.
257. Hu, S.; Qu, Y.; Xu, X.; Xu, Q.; Geng, J.; Xu, J. Nuclear survivin and its relationship to DNA damage repair genes in non-small cell lung cancer investigated using tissue array. PLoS ONE 2013, 8, e74161.[CrossRef]
258. Paulin, R.; Meloche, J.; Jacob, M.H.; Bisserier, M.; Courboulin, A.; Bonnet, S. Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension. Am. J. Physiol. Heart Circ. Physiol. 2011, 301, H1798–H1809.[CrossRef] [PubMed]
259. McMurtry, M.S.; Archer, S.L.; Altieri, D.C.; Bonnet, S.; Haromy, A.; Harry, G.; Bonnet, S.; Puttagunta, L.; Michelakis, E.D. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J. Clin. Investig. 2005, 115, 1479–1491.[CrossRef] [PubMed]
260. Li, M.; Vattulainen, S.; Aho, J.; Orcholski, M.; Rojas, V.; Yuan, K.; Helenius, M.; Taimen, P.; Myllykangas, S.; de Jesus Perez, V.; et al. Loss of bone morphogenetic protein receptor 2 is associated with abnormal DNA repair in pulmonary arterial hypertension. Am. J. Respir. Cell Mol. Biol. 2014, 50, 1118–1128.[CrossRef] [PubMed]
261. De Jesus Perez, V.A.; Yuan, K.; Lyuksyutova, M.A.; Dewey, F.; Orcholski, M.E.; Shuffle, E.M.; Mathur, M.; Yancy, L.; Rojas, V.; Li, C.G. et al. Whole-exome sequencing reveals topbp1 as a novel gene in idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2014, 189, 1260–1272.[CrossRef] [PubMed]
262. Lee, Y.; Katyal, S.; Downing, S.M.; Zhao, J.; Russell, H.R.; McKinnon, P.J. Neurogenesis requires TopBP1 to prevent catastrophic replicative DNA damage in early progenitors. Nat. Neurosci. 2012, 15, 819–826.[CrossRef] [PubMed]
263. Yamane, K.; Wu, X.; Chen, J. A DNA damage-regulated BRCT-containing protein, TopBP1, is required for cell survival. Mol. Cell. Biol. 2002, 22, 555–566.[CrossRef] [PubMed]
264. Mäkiniemi, M.; Hillukkala, T.; Tuusa, J.; Reini, K.; Vaara, M.; Huang, D.; Pospiech, H.; Majuri, I.; Westerling, T.; Mäkelä, T.P.; et al. BRCT domain-containing protein TopBP1 functions in DNA replication and damage response. J. Biol. Chem. 2001, 276, 30399–30406.[CrossRef] [PubMed]
265. Ngo, J.; Matsuyama, M.; Kim, C.; Poventud-Fuentes, I.; Bates, A.; Siedlak, S.L.; Lee, H.; Doughman, Y.Q.; Watanabe, M.; Liner, A. et al. Bax deficiency extends the survival of Ku70 knockout mice that develop lung and heart diseases. Cell Death Dis. 2015, 6, e1706.[CrossRef] [PubMed]
266. Jacquin, S.; Rincheval, V.; Mignotte, B.; Richard, S.; Humbert, M.; Mercier, O.; Londoño-Vallejo, A.; Fadel, E.; Eddahibi, S. Inactivation of p53 is sufficient to induce development of pulmonary hypertension in rats. PLoS ONE 2015, 10, e0131940.[CrossRef] [PubMed]
267. Mizuno, S.; Bogaard, H.J.; Kraskauskas, D.; Alhussaini, A.; Gomez-Arroyo, J.; Voelkel, N.F.; Ishizaki, T. p53 Gene deficiency promotes hypoxia-induced pulmonary hypertension and vascular remodeling in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 2011, 300, L753–L761.[CrossRef] [PubMed]
268. Mouraret, N.; Marcos, E.; Abid, S.; Gary-Bobo, G.; Saker, M.; Houssaini, A.; Dubois-Rande, J.-L.; Boyer, L.; Boczkowski, J.; Derumeaux, G. et al. Activation of lung p53 by Nutlin-3a prevents and reverses experimental pulmonary hypertension. Circulation 2013, 127, 1664–1676.[CrossRef] [PubMed]
269. Potus, F.; LeGuen, M.; Provencher, S.; Meloche, J.; Bonnet, S. DNA damage at the dawn of micro-RNA pathway impairment in pulmonary arterial hypertension. RNA Dis. 2015, 2.[CrossRef]
270. Courboulin, A.; Ranchoux, B.; Cohen-Kaminsky, S.; Perros, F.; Bonnet, S. MicroRNA networks in pulmonary arterial hypertension: Share mechanisms with cancer? Curr. Opin. Oncol. 2016, 28, 72–82.[CrossRef] [PubMed]
271. Fang, E.F.; Scheibye-Knudsen, M.; Chua, K.F.; Mattson, M.P.; Croteau, D.L.; Bohr, V.A. Nuclear DNA damage signalling to mitochondria in ageing. Nat. Rev. Mol. Cell Biol. 2016.[CrossRef] [PubMed]
272. King, A.; Selak, M.A.; Gottlieb, E. Succinate dehydrogenase and fumarate hydratase: Linking mitochondrial dysfunction and cancer. Oncogene 2006, 25, 4675–4682.[CrossRef] [PubMed]
273. Boland, M.L.; Chourasia, A.H.; Macleod, K.F. Mitochondrial dysfunction in cancer. Front. Oncol. 2013, 3, 292.[CrossRef] [PubMed]
274. Sureshbabu, A.; Bhandari, V. Targeting mitochondrial dysfunction in lung diseases: Emphasis on mitophagy. Front. Physiol. 2013, 4.[CrossRef] [PubMed]
275. Tang, X.; Luo, Y.-X.; Chen, H.-Z.; Liu, D.-P. Mitochondria, endothelial cell function, and vascular diseases. Front. Physiol. 2014, 5.[CrossRef] [PubMed]
276. Xu, W.; Koeck, T.; Lara, A.R.; Neumann, D.; DiFilippo, F.P.; Koo, M.; Janocha, A.J.; Masri, F.A.; Arroliga, A.C.; Jennings, C. et al. Alterations of cellular bioenergetics in pulmonary artery endothelial cells. Proc. Natl. Acad. Sci. USA 2007, 104, 1342–1347.[CrossRef] [PubMed]
277. Dromparis, P.; Michelakis, E.D. Mitochondria in vascular health and disease. Annu. Rev. Physiol. 2013, 75, 95–126.[CrossRef] [PubMed]
278. Dromparis, P.; Sutendra, G.; Michelakis, E.D. The role of mitochondria in pulmonary vascular remodeling. J. Mol. Med. 2010, 88, 1003–1010.[CrossRef] [PubMed]
279. Quintero, M.; Colombo, S.L.; Godfrey, A.; Moncada, S. Mitochondria as signaling organelles in the vascular endothelium. Proc. Natl. Acad. Sci. USA 2006, 103, 5379–5384.[CrossRef] [PubMed]
280. Kluge, M.A.; Fetterman, J.L.; Vita, J.A. Mitochondria and Endothelial Function. Circ. Res. 2013, 112, 1171–1188.[CrossRef] [PubMed]
281. Vaseva, A.V.; Moll, U.M. The mitochondrial p53 pathway. Biochim. Biophys. Acta Bioenerg. 2009, 1787, 414–420.[CrossRef] [PubMed]
282. Bonnet, S.; Michelakis, E.D.; Porter, C.J.; Andrade-Navarro, M.A.; Thébaud, B.; Bonnet, S.; Haromy, A.; Harry, G.; Moudgil, R.; McMurtry, M.S. et al. An abnormal mitochondrial–hypoxia inducible factor-1α–Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats similarities to human pulmonary arterial hypertension. Circulation 2006, 113, 2630–2641.[CrossRef] [PubMed]
283. Paulin, R.; Michelakis, E.D. The metabolic theory of pulmonary arterial hypertension. Circ. Res. 2014, 115, 148–164.[CrossRef] [PubMed]
284. Sutendra, G.; Dromparis, P.; Wright, P.; Bonnet, S.; Haromy, A.; Hao, Z.; McMurtry, M.S.; Michalak, M.; Vance, J.E.; Sessa, W.C.; et al. The role of Nogo and the mitochondria-endoplasmic reticulum unit in pulmonary hypertension. Sci. Transl. Med. 2011, 3, 88ra55.[CrossRef] [PubMed]
285. Dromparis, P.; Paulin, R.; Stenson, T.H.; Haromy, A.; Sutendra, G.; Michelakis, E.D. Attenuating endoplasmic reticulum stress as a novel therapeutic strategy in pulmonary hypertension. Circulation 2013, 127, 115–125.[CrossRef] [PubMed]
286. Cottrill, K.A.; Chan, S.Y. Metabolic dysfunction in pulmonary hypertension: The expanding relevance of the Warburg effect. Eur. J. Clin. Investig. 2013, 43, 855–865.[CrossRef] [PubMed]
287. Antigny, F.; Hautefort, A.; Meloche, J.; Belacel-Ouari, M.; Manoury, B.; Rucker-Martin, C.; Péchoux, C.; Potus, F.; Nadeau, V.; Tremblay, E. et al. Potassium-channel subfamily k-member 3 (KCNK3) contributes to the development of pulmonary arterial hypertension. Circulation 2016.[CrossRef] [PubMed]
288. Boucherat, O.; Chabot, S.; Antigny, F.; Perros, F.; Provencher, S.; Bonnet, S. Potassium channels in pulmonary arterial hypertension. Eur. Respir. J. 2015, 46, 1167–1177.[CrossRef] [PubMed]
289. McMurtry, M.S.; Bonnet, S.; Wu, X.; Dyck, J.R.B.; Haromy, A.; Hashimoto, K.; Michelakis, E.D. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ. Res. 2004, 95, 830–840.[CrossRef] [PubMed]
290. Michelakis, E.D.; McMurtry, M.S.; Wu, X.-C.; Dyck, J.R.B.; Moudgil, R.; Hopkins, T.A.; Lopaschuk, G.D.; Puttagunta, L.; Waite, R.; Archer, S.L. Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: Role of increased expression and activity of voltage-gated potassium channels. Circulation 2002, 105, 244–250.[CrossRef] [PubMed]
291. Diebold, I.; Hennigs, J.K.; Miyagawa, K.; Li, C.G.; Nickel, N.P.; Kaschwich, M.; Cao, A.; Wang, L.; Reddy, S.; Chen, P.-I. et al. BMPR2 preserves mitochondrial function and DNA during reoxygenation to promote endothelial cell survival and reverse pulmonary hypertension. Cell Metab. 2015, 21, 596–608.[CrossRef] [PubMed]
292. Fessel, J.P.; Flynn, C.R.; Robinson, L.J.; Penner, N.L.; Gladson, S.; Kang, C.J.; Wasserman, D.H.; Hemnes, A.R.; West, J.D. Hyperoxia synergizes with mutant bone morphogenic protein receptor 2 to cause metabolic stress, oxidant injury, and pulmonary hypertension. Am. J. Respir. Cell Mol. Biol. 2013, 49, 778–787.[CrossRef] [PubMed]
293. Gomez-Arroyo, J.; Mizuno, S.; Szczepanek, K.; van Tassell, B.; Natarajan, R.; dos Remedios, C.G.; Drake, J.I.; Farkas, L.; Kraskauskas, D.; Wijesinghe, D.S. et al. Metabolic gene remodeling and mitochondrial dysfunction in failing right ventricular hypertrophy due to pulmonary arterial hypertension. Circ. Heart Fail. 2013, 6, 136–144.[CrossRef] [PubMed]
294. Sutendra, G.; Dromparis, P.; Paulin, R.; Zervopoulos, S.; Haromy, A.; Nagendran, J.; Michelakis, E.D. A metabolic remodeling in right ventricular hypertrophy is associated with decreased angiogenesis and a transition from a compensated to a decompensated state in pulmonary hypertension. J. Mol. Med. 2013, 91, 1315–1327.[CrossRef] [PubMed]
295. Archer, S.L.; Fang, Y.-H.; Ryan, J.J.; Piao, L. Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension. Pulm. Circ. 2013, 3, 144–152.[CrossRef] [PubMed]
296. Cline, S.D. Mitochondrial DNA damage and its consequences for mitochondrial gene expression. Biochim. Biophys. Acta 2012, 1819, 979–991.[CrossRef] [PubMed]
297. Barja, G.; Herrero, A. Oxidative damage to mitochondrial DNA is inversely related to maximum life span in the heart and brain of mammals. FASEB J. 2000, 14, 312–318.[PubMed]
298. Yakes, F.M.; Van Houten, B. Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proc. Natl. Acad. Sci. USA 1997, 94, 514–519.[CrossRef] [PubMed]
299. Tadi, S.K.; Sebastian, R.; Dahal, S.; Babu, R.K.; Choudhary, B.; Raghavan, S.C. Microhomology-mediated end joining is the principal mediator of double-strand break repair during mitochondrial DNA lesions. Mol. Biol. Cell 2016, 27, 223–235.[CrossRef] [PubMed]
300. Grishko, V.; Solomon, M.; Wilson, G.L.; LeDoux, S.P.; Gillespie, M.N. Oxygen radical-induced mitochondrial DNA damage and repair in pulmonary vascular endothelial cell phenotypes. Am. J. Physiol. 2001, 280, L1300–L1308.
301. López-López, L.; Nieves-Plaza, M.; del Castro, M.R.; Font, Y.M.; Torres-Ramos, C.A.; Vilá, L.M.; Ayala-Peña, S. Mitochondrial DNA damage is associated with damage accrual and disease duration in patients with systemic lupus erythematosus. Lupus 2014, 23, 1133–1141.[CrossRef] [PubMed]
302. Akdogan, A.; Kilic, L.; Dogan, I.; Okutucu, S.; Er, E.; Kaya, B.; Coplu, L.; Calguneri, M.; Tokgozoglu, L.; Ertenli, I. Pulmonary hypertension in systemic lupus erythematosus: Pulmonary thromboembolism is the leading cause. J. Clin. Rheumatol. Pract. Rep. Rheum. Musculoskelet. Dis. 2013, 19, 421–425.[CrossRef] [PubMed]
303. Asherson, R.A. Pulmonary hypertension in systemic lupus erythematosus. J. Rheumatol. 1990, 17, 414–415.[CrossRef] [PubMed]
304. Fetterman, J.L.; Holbrook, M.; Westbrook, D.G.; Brown, J.A.; Feeley, K.P.; Bretón-Romero, R.; Linder, E.A.; Berk, B.D.; Weisbrod, R.M.; Widlansky, M.E.; et al. Mitochondrial DNA damage and vascular function in patients with diabetes mellitus and atherosclerotic cardiovascular disease. Cardiovasc. Diabetol. 2016, 15, 53.[CrossRef] [PubMed]
305. Cheng, Y.; Ren, X.; Gowda, A.S.P.; Shan, Y.; Zhang, L.; Yuan, Y.-S.; Patel, R.; Wu, H.; Huber-Keener, K.; Yang, J.W. et al. Interaction of Sirt3 with OGG1 contributes to repair of mitochondrial DNA and protects from apoptotic cell death under oxidative stress. Cell Death Dis. 2013, 4, e731.[CrossRef] [PubMed]
306. Paulin, R.; Dromparis, P.; Sutendra, G.; Gurtu, V.; Zervopoulos, S.; Bowers, L.; Haromy, A.; Webster, L.; Provencher, S.; Bonnet, S. et al. Sirtuin 3 deficiency is associated with inhibited mitochondrial function and pulmonary arterial hypertension in rodents and humans. Cell Metab. 2014, 20, 827–839.[CrossRef] [PubMed]
307. Szczesny, B.; Brunyanszki, A.; Olah, G.; Mitra, S.; Szabo, C. Opposing roles of mitochondrial and nuclear PARP1 in the regulation of mitochondrial and nuclear DNA integrity: Implications for the regulation of mitochondrial function. Nucleic Acids Res. 2014, 42, 13161–13173.[CrossRef] [PubMed]
308. +SIRT1 Reduction. Cell 2014, 157, 882–896.[CrossRef] [PubMed]